Douglas G. Cole
CIK 1486373 · last filed 2025-06-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$679.2K
Companies
10
Total Filings
52
Lifetime Open-Market Net
-$7.92M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| FHTX | Director | — | $4.18 | — | $0 | 5 | 2025-06-17 |
| SANA | Director | — | $2.68 | — | $0 | 6 | 2024-07-15 |
| Sigilon Therapeutics, Inc. (SGTX) Delisted | Director | — | $22.47 | — | $0 | 4 | 2023-08-11 |
| DNLI | Director | 26,564 | $21.66 | $575.4K | $0 | 8 | 2023-06-05 |
| QTRX | Director | 4,540 | $3.10 | $14.1K | $0 | 2 | 2019-01-04 |
| EDIT | Director | 3,171 | $2.50 | $7.9K | $0 | 3 | 2017-08-21 |
| AGIO | Director | 2,778 | $29.46 | $81.8K | $0 | 3 | 2016-08-11 |
| Receptos, Inc. (RCPT) Delisted | Director | — | — | — | $0 | 1 | 2013-07-19 |
| TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | Director | 0 | — | — | $0 | 2 | 2013-05-20 |
| AVEO PHARMACEUTICALS, INC. (AVEO) Delisted | Director | 23,909 | $15.00 | $358.6K | -$7.92M | 18 | 2011-05-16 |
Recent Filings · Page 2 of 6
52 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-06-08 | SANA | Grant (A) | — | $0 | EDGAR |
| 2022-06-06 | DNLI | Grant (A) | +5,986 | $0 | EDGAR |
| 2022-05-27 | Sigilon Therapeutics, Inc. (SGTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-07-14 | FHTX | Grant (A) | — | $0 | EDGAR |
| 2021-06-28 | Sigilon Therapeutics, Inc. (SGTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-04 | DNLI | Grant (A) | +2,074 | $0 | EDGAR |
| 2021-06-03 | DNLI | Exer (M) | +3,253 | $0 | EDGAR |
| 2021-02-18 | SANA | Grant (A) | — | $0 | EDGAR |
| 2021-02-05 | SANA | Grant (A) | — | $0 | EDGAR |
| 2020-06-05 | DNLI | Grant (A) | — | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.